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ABSTRACT
Objective: This paper explores the use of
pharmacoeconomic methods of valuation to health
impacts resulting from exposure to poor air quality.
In using such methods, interventions that reduce
exposure to poor air quality can be directly compared,
in terms of value for money (or cost-effectiveness),
with competing demands for finite resources, including
other public health interventions.
Design: Using results estimated as part of a health
impact assessment regarding a West Yorkshire Low
Emission Zone strategy, this paper quantifies cost-
saving and health-improving implications of transport
policy through its impact on air quality.
Data source: Estimates of health-related quality of life
and the National Health Service (NHS)/Personal Social
Services (PSS) costs for identified health events were
based on data from Leeds and Bradford using peer-
reviewed publications or Office for National Statistics
releases.
Population: Inhabitants of the area within the outer
ring roads of Leeds and Bradford.
Main outcomes measures: NHS and PSS costs and
quality-adjusted life years (QALYs).
Results: Averting an all-cause mortality death
generates 8.4 QALYs. Each coronary event avoided
saves £28 000 in NHS/PSS costs and generates 1.1
QALYs. For every fewer case of childhood asthma,
there will be NHS/PSS cost saving of £3000 and a
health benefit of 0.9 QALYs. A single term, low
birthweight birth avoided saves £2000 in NHS/PSS
costs. Preventing a preterm birth saves £24 000 in
NHS/PSS costs and generates 1.3 QALYs. A scenario
modelled in the West Yorkshire Low Emission Zone
Feasibility Study, where pre-EURO 4 buses and HGVs
are upgraded to EURO 6 by 2016 generates an
annual benefit of £2.08 million and a one-off benefit
of £3.3 million compared with a net present value
cost of implementation of £6.3 million.
Conclusions: Interventions to improve air quality
and health should be evaluated and where
improvement of population health is the primary
objective, cost-effectiveness analysis using a
NHS/PSS costs and QALYs framework is an
appropriate methodology.
INTRODUCTION
In total, 40 000 deaths are attributable to
exposure to outdoor air pollution, each year
in the UK.1 As a result, there is an increasing
interest in studying the relationship between
air quality and health, and the availability of
evidence to support this association is accu-
mulating;2–4 with air pollution having been
described as ‘the public health problem that
won’t go away’.5 Interventions aimed at
Strengths and limitations of this study
▪ Applying cost and quality-adjusted life year
(QALY) methods from economic evaluation in
healthcare allows the assessment of cost-
effectiveness from a healthcare perspective and
facilitates comparison with other health
interventions.
▪ The methods outlined above will allow local
authorities to prioritise low emission strategies
(supported by health and economic benefits)
alongside other public health interventions.
▪ A fuller consideration of uncertainty would take
in to account the following stochastic elements:
estimated reduction in emissions, modelled dis-
persion, health effects of exposure to air pollu-
tants, values of health impacts and assumptions
made in generating estimates of QALY.
▪ The analysis also only assesses one intervention
(the introduction of pre-EURO 4 buses and HGVs
are upgraded to EURO 6 by 2016). However,
decision-makers are likely to be faced with a
multitude of competing alternatives, both air
quality interventions and other public health
interventions.
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improving air quality incur costs and generate beneﬁts.
Establishing the value for money of these interventions
is a crucial criterion for policymakers’ decision-making.
In particular, it is important that value for money is
established in a manner that is consistent with other
types of intervention to facilitate comparison, for
example, between a strategy that improves air quality
and the introduction of a smoking cessation campaign.
This can ensure that the most cost-effective policies are
implemented to maximise population health given
ﬁxed, or even shrinking, budgets.
To determine cost-effectiveness, we can look to the
methods used by the National Institute for Heath and
Care Excellence (NICE), which is responsible for
making recommendations for health-improving interven-
tions in the UK. NICE has substantial experience in
employing cost-effectiveness evidence to determine
appropriate guidance on the use of pharmacological
treatments, for example, in its decision to not recom-
mend β-interferon and glatiramer acetate for the treat-
ment of multiple sclerosis in 2002.6 Recently, NICE’s
remit has extended to include guidance on public
health interventions for which evidence is also centred
on the estimated cost-effectiveness, for example, guid-
ance on interventions to promote smoking cessation.7
While NICE develops guidance speciﬁcally for England
and Wales, its evidence is often seen internationally and
there are similar organisations that exist in other coun-
tries, for example, PBAC (Australia), CADTH (Canada)
and HITAP (Thailand) to name but three. The process
employed by NICE is rigorous and accountable, and by
employing a generic measure of health, quality-adjusted
life years (QALYs, note that another generic measure of
health, disability-adjusted life years (DALYs), has been
proposed for use with air quality,8 9 but are not discussed
here given that it is not used by NICE), it ensures that
estimates of cost-effectiveness from different types of
health-promoting interventions are comparable and
decision-making consistent. For this reason, this paper
explores the use of a QALY approach to health valuation
and cost-effectiveness analysis to compare interventions
that reduce exposure to poor air quality.
This research is timely for two reasons. First, NICE is
working towards a set of guidance regarding outdoor air
quality and health anticipated to be published in June
2017. And second, air pollution (and in particular road-
trafﬁc pollution) is a major concern in cities throughout
Europe and in particular, the UK. The European
Commission and the Supreme Court has issued a chal-
lenge to the Department for Environment, Food and
Rural Affairs (DEFRA) to ensure full compliance with
nitrogen dioxide (NO2) limit values by 2025. In order to
achieve this, plans for the introduction of ‘clean air
zones’ (CAZs) have been developed throughout the UK.
The CAZ strategies implemented will have similar types
of health outcome to ‘low emission zones’ (LEZs) such
as the West Yorkshire LEZ (WYLEZ) analysed in this
paper. While the proximal motivation for CAZs may be
to achieve compliance, there may well be signiﬁcant
cobeneﬁts in terms of generating health and, indeed, it
may be the case that these interventions are cost-
effective, in terms of health, in their own right.
NICE public health guidance10 describes the potential
methods for the conduct of an economic analysis of
public health programmes including cost-effectiveness
analysis, cost-utility analysis, cost–beneﬁt analysis and
cost-consequence analysis. While this guidance demon-
strates the pros and cons of each type of analysis, it is
not prescriptive in which method is preferred. Where
most of the beneﬁts of an intervention are in the health
sector, it is appropriate to utilise techniques from the
economic evaluation of heath technologies,10 a form of
cost-effectiveness analysis. We consider the use of QALYs
in economic evaluation as a means to quantify any
health impact and provide a basis for calculating the
value for money of air quality interventions, both in
theory and by example through an application of our
estimates to the case study of a policy scenario of the
WYLEZ compared against a ‘do nothing’ scenario.
METHODS
Overview
Following the approach taken by NICE for evaluating
health technologies,10 only National Health Service
(NHS) and Personal Social Services (PSS) costs are
considered in this analysis, with costs falling outside of
these budgets not taken into account, although we
compare our ﬁnal estimate of health-related beneﬁts to
the implementation cost of the scenario under consider-
ation that does not fall on the health sector budget.
Health beneﬁts are quantiﬁed by using the QALY: a
composite measure of number of life years and the
quality weighting associated with this (health-related
quality of life (HRQoL)). The QALY is anchored at 0
(assumed to represent death) and 1 (assumed to repre-
sent full health). NHS/PSS costs and QALYs are mod-
elled over the lifetime of the affected individuals’
lifetime and those falling in future years are both dis-
counted at 3.5% per annum.11 Alternative interventions
can then be compared in terms of their cost and QALY
proﬁles and incremental cost-effectiveness ratios
(ICERs) can then be used to assess cost-effectiveness by
comparing this ICER with the threshold value of a
QALY.10 The threshold value of a QALY represents the
exchange rate between the costs and the effects that is
the rate at which a healthcare decision-maker is willing
to substitute health outcomes and resources. It repre-
sents the opportunity cost of the health foregone in
other areas, by adopting a new technology. While a full
discussion of the underlying theory behind the cost-
effectiveness threshold is beyond the scope of this paper,
it is important to clarify that it is based on an estimate of
the health opportunity cost of healthcare expenditure
(because of constraints such as that imposed by a ﬁxed
budget), rather than the consumption value of health
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(for which estimates of value can be obtained through
methods such as willingness to pay (WTP) or value of a
statistical life (VSL)). Alternatively the threshold value of
a QALY can be used in order to provide valuations in
terms of net monetary (or net health) beneﬁt.12
There is a burgeoning evidence base surrounding
causal links between various health effects, in particular
those affecting chronic morbidity,13–17 and poor air
quality. Replicating WTP surveys to maintain up-to-date
valuations of air quality impacts is expensive and time
consuming (an example survey question is provided in
the online supplementary appendix). Instead, quantify-
ing the beneﬁt associated with air pollution improve-
ment interventions in terms of QALYs and applying an
associated threshold value for a QALY gained provides a
ﬂexible and generalisable approach to estimating the
impact of air quality on health and healthcare costs.
QALYs are less frequently used in environmental eco-
nomics in favour of WTP and VSL methods, but have
great precedent in health economics for quantifying
health effects.18–23 QALYs can also be used as part of
cost–beneﬁt analysis, in which case it may be desirable
to value QALYs using their social consumption value.24
The WYLEZ case study
The West Yorkshire Zone, as classiﬁed by DEFRA, has
the fourth most signiﬁcant NO2 concentration issues in
the UK (after London, West Midlands and Greater
Manchester). In addition, 5.4% of all mortality in West
Yorkshire in 2010 was attributable to exposure to atmos-
pheric particles smaller than 2.5 μm in aerodynamic
diameter (PM2.5).
25 In 2011, Bradford Metropolitan
District Council (BMDC) and Leeds City Council (LCC)
were awarded grants by DEFRA to undertake a LEZ
feasibility study. The work has focused on establishing
the beneﬁts of low emission strategies that could result
from cleaner bus, freight, taxi and private care ﬂeets.
As part of the LEZ feasibility study, Cooper and
colleagues conducted a health impact assessment
(HIA). It is a public document and is available online at
the following URL: http://www.bradford.gov.uk/NR/
rdonlyres/1B122A0C-D989-451D-B0BE-30A46F0FF569/0/
ReportOfTheLEZFeasibilityStudy.pdf. This HIA com-
prises several parts: modelling of trafﬁc and emissions
under different policy scenarios, dispersion modelling, a
model to convert concentrations into lower layer super
output area (LSOA)-level exposure and the application
of response functions that generate estimates of changes
in numbers of health events given changes in exposure
and baseline levels of health events. Full details can be
obtained from the document itself, but some key fea-
tures for the purposes of this paper are described below.
The HIA looked only at the long-term health effects
from exposure to PM2.5 and NO2. The health effects of
other pollutants such as ozone were therefore not con-
sidered. In addition, the acute health effects of short-
term exposure to air pollutants were not considered.
These health effects are likely to be of a smaller magni-
tude than those considered26 and so would be unlikely
to inﬂuence results. Estimates of the quantitative impact
on health from exposure to poor air quality are taken
from studies that were considered high quality either
through being a meta-analysis identiﬁed through
PubMed13–17 or by virtue of being a study that is heavily
cited and recommended by COMEAP.15 The resulting
studies, details regarding study type and their estimated
effects on health are shown below in table 1.
In certain cases, more recent meta-analyses have
become available and more widely used than those used
in the original HIA, for instance all-cause mortality due
to PM2.5 exposure in ref. 27. In addition, more health
Table 1 Exposure response functions from Cooper et al30
Health event Pollutant Reference Study type
Type of
effect Exposure response function
All-cause
mortality death
PM2.5 Pope,
et al15
Cohort study (USA) Annual Relative risk of 1.06 (95% CI 1.02 to
1.11) per 10 μg/m3 increase in PM2.5
exposure
Coronary
events
(Bradford only)
PM2.5 Cesaroni,
et al13
Meta-analysis of cohort
studies (Europe, not
including UK)
Annual HR of 1.19 (95% CI 1.00 to 1.42) per
5 μg/m3 increase in PM2.5 exposure
Cases of
childhood
asthma
NO2 Takenoue,
et al17
Meta-analysis
(worldwide, not including
UK)
Prevalence OR of 1.135 (95% CI 1.03 to 1.25)
per 18.8 μg/m3 increase in NO2
Term, low
birthweight birth
PM2.5 and
NO2
Pedersen
et al14
Pooled cohort studies
(Europe, including UK—
born in Bradford)
Annual OR of 1.18 (95% CI 1.06 to 1.33) per
5 μg/m3 increase in PM2.5 exposure
and 1.09 (95% CI 1.00 to 1.19) per
10 μg/m3 increase in NO2
Preterm birth PM2.5 Sapkota,
et al16
Meta-analysis
(worldwide, not including
UK)
Annual OR of 1.15 (95% CI 1.14 to 1.16) per
10 μg/m3 increase in PM2.5 exposure
PM2.5, atmospheric particles smaller than 2.5 μm in aerodynamic diameter.
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conditions have been linked with poor air quality expos-
ure, without a meta-analysis having been performed (eg,
see ref. 28, for incidence of bronchitis). In this paper,
the links used in the published HIA are taken as given.
The purpose of the paper is to apply the NICE frame-
work and to demonstrate the application of a new meth-
odology to the ﬁeld of air quality using a real-world case
study. The paper explores the use of cost-effectiveness
analysis to inform local decision-making in WYLEZ,
working with locally available data where possible. As
can be seen in table 1, only one of the health events is
modelled as a response to exposure of both pollutants.
Therefore, any double counting through modelling
term, low birthweight births as a response to both pollu-
tants independently is likely to have only a small impact
on results obtained. However, this is a bigger consider-
ation in the broader literature where many of the same
outcomes can result from PM2.5 and NO2 and very often
people are simultaneously exposed to both (see for
instance discussion in ref. 29). In addition, there may be
synergistic effects arising from exposure to both that are
not considered in the analysis here. The study also
assumed that there was no time lag between exposure to
pollutants and the resulting health events; this is again
another simpliﬁcation that should be taken into account
when looking at the results (see ref. 26 for further
details on issues around modelling this lagged effect of
exposure).
In this analysis, the health effects of one intervention
(pre-EURO 4 buses and HGVs were upgraded to EURO
6 by 2016) were taken from an analysis undertaken as
part of the LEZ feasibility studies.30 i The comparison is
with a 2012 baseline (no intervention).
The health effects of this scenario relative to no inter-
vention were taken from LSOAs with centroids within
the outer ring roads (ORRs) in Leeds and Bradford
resulting from estimated reductions in emissions from
within Leeds and Bradford ORRs of 13.502 t of PM2.5
per annum and 352.28 t of NOx per annum (where 50%
of NOx is assumed to be NO2 for the purposes of the
HIA). This is the change in emissions relative to the
2012 baseline that acts as the comparator in this evalu-
ation, which results from the change in trafﬁc-related
emissions (background concentrations of pollutants are
common to both scenarios and therefore do not affect
the changes in exposure). Note that here a conservative
assumption has been applied in terms of limiting the
health effects to within the same area as impacted by the
introduction of the LEZ. This underestimates the health
impacts for two reasons. One is that a LEZ will affect
trafﬁc and so emissions and exposure in the surround-
ing area. The other is that emissions within the LEZ are
dispersed and so may cause exposure outside of the LEZ
itself. Both of those would be captured in an ideal ana-
lysis, but in this paper, we apply a practical simpliﬁcation
that represents a lower bound on the health effects of
the policy.
Estimating the NHS/PSS costs and QALYs associated with
air quality-related health endpoints
Obtaining estimates of HRQoL and NHS/PSS costs for
each of the events in the HIA requires some assumptions,
which are detailed elsewhere.31 An example of such an
assumption pertains to the conversion of attributable
deaths to QALYs. According to ref. 26, exposure to PM2.5
leads to roughly 29 000 attributable deaths in the UK and
340 000 life years lost. We therefore assume that 11.72 life
years are lost for each attributable death. In addition, we
assume that each person affected loses 2 years of life
(5.86 people affected per attributable death) and that
they were in 75+ age category (HRQoL for this age group
is 0.73 on average according to ref. 32). After discount-
ing, the health loss associated with an attributable death
is 8.4 QALYs. A summary of the sources used is provided
in table 2.ii
For each of the health impacts estimated from the
HIA, the QALYs lost and additional NHS and PSS
resources used were evaluated. The central estimates of
the value of these health impacts when following this
approach (and valuing a QALY at £20 000) are given in
table 3. Full details of their calculation can be found in
ref. 31 (see online supplementary appendix for full
URL of this publication). The inclusion of QALYs and
NHS/PSS costs is consistent with a pharmacoeconomic
approach to cost-effectiveness analysis, such as that typic-
ally adopted by NICE for the evaluation of interventions
where costs largely fall on the health sector.
RESULTS
In this section, we present the results for the valuation
of this LEZ scenario using the approach discussed in the
previous section. The results from these are summarised
in table 4.
The HIA considers more health outcomes than mortal-
ity, with morbidity cases averted forming a substantial pro-
portion of the value of health beneﬁts generated from
reducing exposure to trafﬁc-related air pollution. These
include neonatal complications arising from air pollution
as well as NHS/PSS costs of childhood asthma cases. The
single largest component of the annual effect is from the
impact of reduced PM2.5 on reduced all-cause mortality
where 10 equivalent deaths are averted. These are valued
at £1 680 000 per year. This constitutes over three-
quarters of the total annual effect (the weight attached to
iAvailable for download as ‘Bradford Low Emission Zone Feasibility
Study’ at http://www.bradford.gov.uk/bmdc/the_environment/
pollution_noise_and_nuisance/air_quality.
iiData that can be made available can be obtained by contacting the
corresponding author (JL) at james.lomas@york.ac.uk. These data take
the form of a spreadsheet in which calculations were made. Baseline
data to which response functions were applied are not able to be made
publicly available due to small numbers of counts.
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mortality vs morbidity is variable among competing meth-
odologies, as can be seen in ref. 44, where the percentage
due to mortality is higher when VSL applied to attribut-
able deaths compared with value of life year applied to
life years). The remainder of the annual effect is made
up of morbidity effects of other health impacts averted
through reduction in exposure to PM2.5 (and some mor-
tality effects due to pre term birth). Within the annual
effect, roughly 1% is made up of health impacts averted
due to reduced exposure to NO2. However, there is a sub-
stantial one-off value of £3 300 000 attached to the reduc-
tion in prevalence of childhood asthma that results from
reduced exposure to NO2.
DISCUSSION
This paper highlights the potential to apply a method for
assessing the likely cost-effectiveness of interventions to
promote air quality that has been developed for the
assessment of pharmacoeconomic interventions, includ-
ing those appraised by NICE. Our results indicate an esti-
mate of the annual value of the health impact of this
intervention of £2 080 000 per annum alongside a
one-off effect on prevalence of childhood asthma worth
£3 300 000. According to ref. 21, the net present value of
the cost of implementing this scenario is £6 300 000.
Thus, the intervention appears to be cost-effective if dif-
ferences in exposure are maintained for a sufﬁciently
long time period (roughly 1 year and 5 months assuming
discount rate of 3.5%).iii However, a more careful consid-
eration of alternative interventions should be used to
inform a policymaker and the focus of this paper is meth-
odological and the application is illustrative.
The use of cost-effectiveness analysis using QALY as an
outcome measure is common in health technology
assessment. Though there are examples of a QALY
framework being applied to evaluate air quality interven-
tions,45–47 these are relatively rare. While the advantages
of the NHS/PSS costs and QALYs approach are substan-
tial, allowing the comparison across a variety of interven-
tions in different conditions, the approach also has its
limitations and difﬁculties in public health evaluations.48
At present, the NHS/PSS costs and QALYs approach is
used primarily where the perceived beneﬁts are in the
health sector. Ongoing work49 is exploring the potential
for extending the health sector costs and QALYs
approach to a multisectoral environment. However, this
work remains in its infancy and approaches that allow
the comparison of outcomes across several sectors (such
as the damage cost method) have been preferred where
substantial effects extend beyond health.
Where interventions to improve air quality are primar-
ily aimed at improving health, should they not be com-
pared with other health interventions, so that scarce
resources can be used most efﬁciently? In these
instances, there appears to be little justiﬁcation to
exclude air quality interventions from comparison with
other ‘health’ interventions. In order to facilitate this
comparison, the use of QALYs is desirable, which has
been illustrated successfully in this paper.
Strengths
Applying cost and QALY methods from economic evalua-
tioniv in healthcare allows the assessment of cost-
effectiveness from a healthcare perspective and facilitates
comparison with other health interventions. There is cur-
rently a robust health economic evidence base support-
ing some key public health interventions (eg, smoking
cessation, alcohol screening and brief interventions, pre-
scribing exercise classes).v Recent research by COMEAP
and others has demonstrated how poor air quality should
join the list of public health priorities. Looking at
Table 3 Summary of NHS/PSS costs and QALYs
associated with each case of the health end points from
the HIA
Health outcome
QALY
loss,
one
decimal
place
Additional
costs,
nearest
£1000 (£
2013/2014)
Combined
loss,
nearest
£1000 (£
2013/2014)
All-cause death 8.4 – £168 000
Coronary event 1.1 £28 000 £50 000
Term, low
birthweight birth
− £2000 £2000
Preterm birth 1.3 £24 000 £50 000
Childhood asthma 0.9 £3000 £21 000
HIA, health impact assessment; NHS, National Health Service;
PSS, Personal Social Services; QALY, quality-adjusted life year.
Table 2 Data sources for cost and quality-adjusted life
year estimates
Health event
Sources used for
health cost calculation
All-cause mortality death 32 26
Coronary events (Bradford only) 32–37
Cases of childhood asthma 32–35 37–41
Term, low birthweight birth 33
Preterm birth 33 32 42 43
iiiThe time horizon over which a decision-maker would take into
account costs and beneﬁts is clearly an important issue in this scenario,
but this is true more broadly in terms of air quality, public health or
even medical evaluations. In principle, the appropriate time horizon
would be the period over which costs and beneﬁts are different for
comparators under consideration. In practice, however, one might
adopt a time horizon in keeping with the speciﬁc policy under
consideration, for example, the expected longevity of new buses.
ivIt should be noted that we use the term evaluation, whereas the more
precise wording might be ex ante evaluation, since we are constructing
a model to evaluate the effects of an intervention before it has been
implemented. Ex post evaluation refers to an analysis of an intervention
after it has taken place, typically by examining changes in outcomes
following its implementation.
vSee NICE website: https://www.nice.org.uk/guidance/published?
type=ph.
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England only, there were 80 000 deaths due to smoking
among adults over 35 in 201350 and 6500 deaths related
to alcohol in 2012.51 This compares with 40 000 attribut-
able deaths per year in the UK.1 The methods outlined
above will allow local authorities to prioritise low emission
strategies (supported by health and economic beneﬁts)
alongside other public health interventions.
Limitations
It is worth noting that it may not always be possible to
estimate an effect of a health event on QALYs or NHS/
PSS costs due to data limitations or potentially a lack of
sensitivity in the instrument for measuring health. One
such example was our inability to estimate a QALY loss
associated with term, low birthweight birth. In such
cases, it is worth considering the total health effects that
can be assigned a QALY loss as potentially a lower
bound, since others may exist but cannot be valued for
one of the reasons above. It is also worth noting that if
the issue is that the health effect is too small to be
detected, then it is unlikely to have a large bearing on
decision-making.
The results presented above only consider a point esti-
mate for the effects of the LEZ scenario, this masks the
large uncertainty associated with each of the estimated
components. One such uncertainty arises from the
length of lag between exposure and health effect.
Indeed this is one aspect of uncertainty, but there are
many more that are relevant to the decision-maker.
Presenting only the point estimates is useful for a com-
parison of the expected values generated by the LEZ
scenario. A fuller consideration of uncertainty would
take in to account the following stochastic elements:
1. Estimated reduction in emissions;
2. Modelled dispersion;
3. Health effects of exposure to air pollutants;
4. Values of health impacts;
5. Assumptions made in generating estimates of QALY.
The analysis makes only one comparison between the
introduction of pre-EURO 4 buses and HGVs are
upgraded to EURO 6 by 2016 and a preintervention
(2012) baseline. However, decision-makers are likely to
be faced with a multitude of competing alternatives,
both air quality interventions and other public health
interventions. Thus, a more useful analysis would
include an assessment of the cost-effectiveness of several
relevant comparators rather than comparing one inter-
vention with a preintervention baseline. Importantly, the
principle of using a common measure of beneﬁt (such
as QALYs) is crucial for aiding comparison. There are
projections of how the transport ﬂeet may evolve that is
often referred to as a ‘do nothing’ scenario, which is the
preferred comparator in ref. 21. However, it is poten-
tially preferable to use the preintervention baseline if
the assumptions underlying the projection are question-
able. For example, enforcing the ‘do nothing’ projec-
tions may not be without cost if neighbouring regions
implemented a LEZ and the associated consequences in
terms of relocation of older vehicles within the national
transport ﬂeet. The purpose of the case study is to illus-
trate the cost-effectiveness methodology using QALYs as
a measure of health beneﬁts, based on NICE guidance.
We only claim that the illustration is generalisable to the
extent that the health effects considered would be
common to similar types of interventions under consid-
eration. These would include CAZs across UK and there-
fore this paper will be useful to local decision-makers
across the country. However, there are many speciﬁc fea-
tures of the case study and the interested reader may
wish to investigate other similar studies if they are inter-
ested in the evaluation of air pollution policy more gen-
erally (see for instance refs. 22, 23 and 52).
In the context of a transport intervention, further costs
may be of interest, for instance those that fall on bus com-
panies, or on council-provided services or sectors such as
the educational sector. The illustration in this paper pro-
vides valuable information on the health sector conse-
quences, but further research on the impacts on other
sectors would be complementary and valuable.
CONCLUSION
Interventions to improve air quality and health should be
evaluated and where improvement of population health
is the primary objective, cost-effectiveness analysis using
Table 4 Summary of results
Health event Pollutant
Number averted per year by implementing
pre EURO 4 buses and HGVs were
upgraded to EURO 6 by 2016
Total value per year,
nearest £10 000 (£ 2013/2014)
All-cause mortality death PM2.5 10 £1 680 000
Coronary events (Bradford only) PM2.5 5 £250 000
Term, low birthweight birth PM2.5 7 £20 000
Term, low birthweight birth NO2 10 £20 000
Preterm birth PM2.5 2.2 £110 000
Total annual effect £2 080 000
Cases of childhood asthma NO2 157 £3 300 000*
*Not annual effect but rather a one-off reduction in cases due to reduced prevalence.
NO2, nitrogen dioxide; PM2.5, atmospheric particles smaller than 2.5 μm in aerodynamic diameter.
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the NICE reference case with NHS/PSS costs and QALYs
framework is an appropriate methodology. Alternative
methodologies exist such as cost–beneﬁt analysis, which
has greater precedence in the environment literature. It
should be noted that NHS/PSS costs and QALYs can be
used as an input into cost–beneﬁt analysis also.
Author affiliations
1University of York, Centre for Health Economics, York, UK
2Academic Unit of Health Economics, University of Leeds, Leeds, UK
3City of Bradford Metropolitan District Council, Bradford, UK
4Improvement Academy, Yorkshire and Humber Academic Health Science
Network, UK
5City of York Council, York, UK
6Ecometrics Research and Consulting, Reading, UK
7Wakefield Council, Wakefield, UK
8Leeds City Council, Leeds, UK
9CREAL (Centre de Recerca en Epidmiologia Ambiental)
Acknowledgements This article presents independent research by the
National Institute for Health Research Collaboration for Leadership in Applied
Health Research and Care Yorkshire and Humber (NIHR CLAHRC YH). www.
clahrc-yh.nir.ac.uk. The views and opinions expressed are those of the
authors, and not necessarily those of the NHS, the NIHR or the Department of
Health. In addition, helpful comments were provided at earlier presentations
of this work at Public Health England’s Annual UK Review Meeting on
Outdoor and Indoor Air Pollution Research and the Air Quality Improvement
Collaborative Event. The authors are extremely grateful to the reviewers who
provided a comprehensive and constructive evaluation of the paper, from
which the paper has greatly benefited. They also acknowledge funding from
DEFRA, during the time period over which the study was conducted. The
authors acknowledge funding from a broad range of organisations.
Governmental organisations include UK government (Environment Agency,
Defra, Department for Health), the European Commission, WHO and OECD.
NGOs include the Health Environment Alliance, European Environment Bureau
and Greenpeace. MH’s work is funded by some industrial organisations, but
none relevant to local air quality.
Contributors JL was responsible for the initial draft before comments
from all authors and led the conduct of the analysis that formed the
basis of the paper. LS contributed to the drafting of the paper in addition to
having provided input into the analysis undertaken. SJ, MM and EB
commented on several versions of the draft and analysis as well as having
helped to set the overall direction for the paper. MH, MA, DRR and HW
provided substantial comments on the draft and analysis, and provided
expertise on related work. DC provided substantial comments on the draft and
analysis and was responsible for the initial health impact analysis on which
this work is based. RC provided substantial input and comments on the
analysis and was contributed greatly to the initial health impact analysis on
which this work is based. GR and LB were heavily involved in the drafting and
conduct of analysis as well as having helped to set the overall direction for
the paper.
Funding National Institute for Health Research (NIHRCLAHRCYH).
Disclaimer The views and opinions expressed are those of the authors, and
not necessarily those of the NHS, the NIHR or the Department of Health.
Competing interests RC reports a grant from DEFRA, during the conduct of
the study. MH is funded by a broad range of organisations. Governmental
organisations include UK government (Environment Agency, Defra,
Department for Health), the European Commission, WHO and OECD. NGOs
include the Health Environment Alliance, European Environment Bureau and
Greenpeace. MH’s work is also funded by some industrial organisations, but
none relevant to local air quality.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the terms of the Creative Commons Attribution (CC BY 4.0) license, which
permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/
REFERENCES
1. Royal College of Physicians. Every breath we take: the lifelong
impact of air pollution. London: RCP, 2016.
2. Brauer M. Air pollution, stroke, and anxiety. BMJ 2015;350:h1510.
3. Power MC, Kioumourtzoglou M-A, Hart JE, et al. The relation
between past exposure to fine particulate air pollution and prevalent
anxiety: observational cohort study. BMJ 2015;350:h1111.
4. Shah ASV, Lee KK, McAllister DA, et al. Short term exposure to air
pollution and stroke: systematic review and meta-analysis. BMJ
2015;350:h1295.
5. Hawkes N. Air pollution in UK: the public health problem that won’t
go away. BMJ 2015;350:h2757.
6. NICE. Beta interferon and glatiramer acetate for the treatment of
multiple sclerosis. 2002. https://www.nice.org.uk/guidance/ta32
(accessed 1 Jun 2016).
7. NICE. Smoking: workplace interventions. 2007. https://www.nice.org.
uk/guidance/ph5 (accessed 1 Jun 2016).
8. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of
burden of disease and injury attributable to 67 risk factors and risk
factor clusters in 21 regions, 1990–2010: a systematic analysis for
the Global Burden of Disease Study 2010. Lancet
2012;380:2224–60.
9. Martenies SE, Wilkins D, Batterman SA. Health impact metrics for
air pollution management strategies. Environ Int 2015;85:84–95.
10. NICE. Methods for the development of NICE public health guidance.
3rd edn. 2012.
11. Treasury HM. The Green Book: appraisal and evaluation in central
government. 2013. https://www.gov.uk/government/publications/the-
green-book-appraisal-and-evaluation-in-central-governent (accessed
1 Jun 2016).
12. Claxton K. The irrelevance of inference: a decision-making approach
to the stochastic evaluation of health care technologies. J Health
Econ 1999;18:341–64.
13. Cesaroni G, Forastiere F, Stafoggia M, et al. Long term exposure to
ambient air pollution and incidence of acute coronary events:
prospective cohort study and meta-analysis in 11 European cohorts
from the ESCAPE Project. BMJ 2014;348:f7412.
14. Pedersen M, Giorgis-Allemand L, Bernard C, et al. Ambient air
pollution and low birthweight: a European cohort study (ESCAPE).
Lancet Respir Med 2013;1:695–704.
15. Pope CA, Burnett RT, Thun MJ. Lung cancer, cardiopulmonary
mortality, and long-term exposure to fine particulate air pollution.
JAMA 2002;287:1132–41.
16. Sapkota A, Chelikowsky AP, Nachman KE, et al. Exposure to
particulate matter and adverse birth outcomes: a comprehensive
review and meta-analysis. Air Qual Atmos Health 2012;5:369–81.
17. Takenoue Y, Kaneko T, Miyamae T, et al. Influence of outdoor NO2
exposure on asthma in childhood: meta-analysis. Pediatr Int
2012;54:762–9.
18. Arigoni Ortiz R, Markandya A, Hunt A. Willingness to pay for
mortality risk reduction associated with air pollution in São Paulo.
Rev Bras Econ 2009;63:3–22.
19. Chilton S, Covey J, Jones-Lee M, et al. Health benefits associated
with reductions in air pollution. 2004.
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